A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

Journal of the American Geriatrics Society

Volumn 49, Issue 12, 2001, Pages 1590-1599

  Tariot, Pierre N ^a   Cummings, Jeffrey L ^b   Katz, Ira R ^c   Mintzer, Jacobo ^d   Perdomo, Carlos A ^e   Schwam, Elias M ^f   Whalen, Edward ^f  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e EISAI INC   (United States)

^f PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Cognition; Donepezil; Nursing home

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL TEST; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; MYASTHENIA; NAUSEA; NURSING HOME; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; TREMOR; VERTIGO; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NURSING HOMES; OUTCOME ASSESSMENT (HEALTH CARE); PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 0035661596     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2001.t01-1-49266.x     Document Type: Article

References (50)

1. Prevalence of Alzheimer's disease in a community population of older persons
2. Behavior disturbance and other predictors of carer burden in Alzheimer's disease
3. Dementia caregiver burden: A review of the literature and guidelines for assessment and intervention
4. Incontinence and troublesome behaviors predict institutionalization in dementia
5. Prevalence of mental illness in a community nursing home
6. Mental disorders in the nursing home: Another perspective
7. Potential cost savings in residential care for Alzheimer's disease patients
8. Therapy of the cognitive deficit in Alzheimer's disease: The cholinergic system
9. Cholinesterase inhibitors: A new class of psychotropic compounds
10. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
11. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
12. Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease
13. Donepezil in Alzheimer's disease: Relative cognitive and neuropsychiatric responses and impact on caregiver distress
14. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
15. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease
16. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes
17. Reducing antipsychotic drug use in nursing homes. A controlled trial of provider education
18. Pharmacologic treatment of depression in the elderly
19. E2020: The pharmacology of a piperidine cholinesterase inhibitor
20. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
21. Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study
22. The effects of donepezil in Alzheimer's disease-results from a multinational trial
23. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients
24. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
25. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a U.S. multicentre open-label study
26. An open-label, multicenter, phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer's disease
27. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects
28. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses
29. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force in Alzheimer's disease
30. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician
31. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia
32. The use of the neuropsychiatric inventory in nursing home residents: Characterization and measurement
33. Rating chronic medical illness medical burden in geropsychiatric practice and research: Application of the cumulative illness rating scale
34. Validation of the cumulative illness rating scale in a geriatric residential population
35. Reliability and validity of a chronic care facility adaptation of the clinical dementia rating scale
36. Assessment of older people: Self-maintaining and instrumental activities of daily living
37. A new clinical scale for the staging of dementia
38. The Clinical Dementia Rating (CDR): Current version and scoring rules
39. Neuroscience, neurology and neuropsychiatry: Responding to an aging population
40. Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's disease
41. Behavioural management in nursing and residential homes: A randomised controlled trial
42. Agitation in elderly persons: An integrative report of findings in a nursing home
43. Longitudinal evaluation of dementia of the Alzheimer's type: A comparison of 3 standardized mental status examinations
44. Cognitive decline in Alzheimer's disease: Elaborating on the nature of the longitudinal factor structure of the mini-mental state examination
45. Measuring cognitive change in a cohort of patients with Alzheimer's disease
46. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention
47. Efficacy and safety results of the early phase studies with Exelon™ (ENA-713) in Alzheimer's disease: An overview
48. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: An update